http://www.xconomy.com/seattle/2009/05/31/bipar-sciences-vulcan-backed-biotech-helps-women-live-longer-with-breast-cancer/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/seattle/2009/05/31/bipar-sciences-vulcan-backed-biotech-helps-women-live-longer-with-breast-cancer/comment-page-1/#comment-62477 PARP inhibitors at ASCO: a new appraoch to breast cancer treatment? | Pharma Marketer Mon, 01 Jun 2009 14:26:57 +0000 http://www.xconomy.com/?p=27223#comment-62477 [...] articles by Zemanta BiPar Sciences, Vulcan-Backed Biotech, Helps Women With Breast Cancer Live Longer [...] [...] articles by Zemanta BiPar Sciences, Vulcan-Backed Biotech, Helps Women With Breast Cancer Live Longer [...]

]]> http://www.xconomy.com/seattle/2009/05/31/bipar-sciences-vulcan-backed-biotech-helps-women-live-longer-with-breast-cancer/comment-page-1/#comment-62191 ASCO Weekend Roundup Part 1 - Focus on BiPar | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky Sun, 31 May 2009 21:30:07 +0000 http://www.xconomy.com/?p=27223#comment-62191 [...] news is getting a lot of hype/press: coverage on Xconomy, coverage on Forbes, this great Bloomberg write-up and the fact that BiPar’s 5-year financing [...] [...] news is getting a lot of hype/press: coverage on Xconomy, coverage on Forbes, this great Bloomberg write-up and the fact that BiPar’s 5-year financing [...]

]]> http://www.xconomy.com/seattle/2009/05/31/bipar-sciences-vulcan-backed-biotech-helps-women-live-longer-with-breast-cancer/comment-page-1/#comment-62170 Fred Moolten Sun, 31 May 2009 20:26:34 +0000 http://www.xconomy.com/?p=27223#comment-62170 A number of PARP inhibitors have shown promise in retarding breast cancer growth, and are particularly promising in women with BRCA1 or BRCA2 mutations, which impair the ability of the cancer cells to repair DNA damage, and thus increase sensitivity to the inhibitors. However, the word "Bombshell" is very unfortunate in that it will raise expectations beyond what has been achieved to date. The results are modest. They should be celebrated and built upon, but not exaggerated with attention-grabbing headlines. A number of PARP inhibitors have shown promise in retarding breast cancer growth, and are particularly promising in women with BRCA1 or BRCA2 mutations, which impair the ability of the cancer cells to repair DNA damage, and thus increase sensitivity to the inhibitors. However, the word “Bombshell” is very unfortunate in that it will raise expectations beyond what has been achieved to date. The results are modest. They should be celebrated and built upon, but not exaggerated with attention-grabbing headlines.

]]> http://www.xconomy.com/seattle/2009/05/31/bipar-sciences-vulcan-backed-biotech-helps-women-live-longer-with-breast-cancer/comment-page-1/#comment-62153 Breast Cancer Bombshell: Vulcan-Backed BiPar Wows Scientists, Helps … - Xconomy « AddingInfo.com Sun, 31 May 2009 19:09:08 +0000 http://www.xconomy.com/?p=27223#comment-62153 [...] had some clinical benefit when they got the BiPar treatment, which researchers defined as … Read Full Post: Breast Cancer Bombshell: Vulcan-Backed BiPar Wows Scientists, Helps … - Xconom... Adding Related Info:New Roche drug helps shrink breast cancer tumors - ReutersNew Roche Drug Helps [...] [...] had some clinical benefit when they got the BiPar treatment, which researchers defined as … Read Full Post: Breast Cancer Bombshell: Vulcan-Backed BiPar Wows Scientists, Helps … – Xconom… Adding Related Info:New Roche drug helps shrink breast cancer tumors – ReutersNew Roche Drug Helps [...]

]]>